成都苑东生物制药股份有限公司 第四届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 证券代码：688513 证券简称：苑东生物 公告编号：2025-057 成都苑东生物制药股份有限公司（以下称"公司"）第四届董事会第七次会议 于 2025 年 8 月 18 日以现场和通讯相结合的方式召开。会议通知已于 2025 年 8 月 8 日以专人送达、电话通知、电子邮件等形式送达全体董事。本次会议由董事 长王颖女士主持，应出席董事 9 名，实际出席董事 9 名。本次会议的召集、召开 和表决程序符合《中华人民共和国公司法》等相关法律法规和《成都苑东生物制 药股份有限公司章程》的规定，会议形成的决议合法有效。 二、董事会会议审议情况 经与会董事审议，逐项表决，形成决议如下： （一）审议通过《关于<公司 2025 年半年度报告及其摘要>的议案》 董事会同意《关于<公司 2025 年半年度报告及其摘要>的议案》。 表决结果：9 票赞成，0 票反对，0 票弃权。同意票占本次董事会有效表决 票数 ...

公司代码：688513 公司简称：苑东生物 成都苑东生物制药股份有限公司 1 / 200 2025 年半年度报告 成都苑东生物制药股份有限公司2025 年半年度报告 成都苑东生物制药股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告中详细阐述公司在生产经营过程中可能面临的各种风险及应对措施，敬请查 阅第三节"管理层讨论与分析"之"四、风险因素"。敬请投资者予以关注，注意投资风险。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人王颖、主管会计工作负责人伯小芹及会计机构负责人（会计主管人员）伯小芹 声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的公司未来计划、发展战略等前瞻性陈述，不构成公司对投资 ...

Group 1 - The chemical pharmaceutical sector increased by 2.34% on August 13, with Shouyao Holdings leading the gains [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] - Notable gainers in the chemical pharmaceutical sector included Shouyao Holdings, which rose by 19.99% to a closing price of 55.94, and Weichip Bio, which increased by 14.39% to 41.18 [1] Group 2 - The chemical pharmaceutical sector saw a net inflow of 342 million yuan from main funds, while retail investors contributed a net inflow of 426 million yuan [2] - Major stocks with significant net inflows included Heng Rui Pharmaceutical with 55.1 million yuan and Fu Xing Pharmaceutical with 23.4 million yuan [3] - Conversely, stocks like ST Sailong and ST Suwu experienced notable net outflows of 4.97% and 3.70%, respectively [2]

金融界消息 截至2025年8月8日收盘，苑东生物（688513）报收于59.5元，下跌0.93%，换手率1.85%， 成交量3.27万手，成交金额1.94亿元。 资金流向方面，今日主力资金净流出1877.20万元，占比成交额9.67%。其中，超大单净流出1164.09万 元、占成交额6.0%，大单净流出713.11万元、占成交额3.67%，中单净流出流出837.36万元、占成交额 4.31%，小单净流入2714.56万元、占成交额13.99%。 苑东生物最新一期业绩显示，截至2025一季报，公司营业总收入3.06亿元、同比减少2.97%，归属净利 润6059.04万元，同比减少19.22%，扣非净利润4646.87万元，同比减少10.79%，流动比率3.365、速动比 率3.005、资产负债率20.17%。 天眼查商业履历信息显示，成都苑东生物制药股份有限公司，成立于2009年，位于成都市，是一家以从 事医药制造业为主的企业。企业注册资本17653.2256万人民币，实缴资本8650万人民币。公司法定代表 人为王颖。 通过天眼查大数据分析，成都苑东生物制药股份有限公司共对外投资了12家企业，参与招投标项目34 ...

Group 1 - The chemical pharmaceutical sector increased by 0.48% on August 4, with Hai Chen Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] - Hai Chen Pharmaceutical's stock price rose by 20.01% to 41.27, with a trading volume of 285,300 shares and a transaction value of 1.101 billion [1] Group 2 - The top gainers in the chemical pharmaceutical sector included Han Yu Pharmaceutical, which rose by 19.98% to 24.32, and Guangsheng Tang, which increased by 18.18% to 120.90 [1] - The sector saw a net inflow of 97.0043 million in main funds, while retail investors contributed a net inflow of 1.279 billion [2] - The main funds showed significant net outflows in several companies, including Hai Chen Pharmaceutical, which had a net inflow of 182 million, but retail investors had a net outflow of 579.696 million [3]

Group 1 - The company announced the approval of the resolution to remove Mr. Peng Long from the position of independent director during the first extraordinary general meeting of shareholders in 2025 [2] - The company also approved the resolution to elect a new independent director for the fourth board of directors [2]

证券代码：688513 证券简称：苑东生物 公告编号：2025-054 成都苑东生物制药股份有限公司 注：计算出席会议的股东（普通股股东）所持有的表决权数量占公司表决权数量的比例已剔 除本次股权登记日登记在册的公司股票回购专户所持有的股份。 （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长王颖女士主持，会议采用现场投票和网 络投票相结合的表决方式。本次股东大会的召集和召开程序、出席会议人员的资 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 8 月 1 日 （二） 股东大会召开的地点：四川省成都市双流区安康路 8 号，苑东生物 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 69 | | --- | --- | | 普通股股东人数 ...

植德京(会)字[2025]0104 号 北京植德律师事务所 关于成都苑东生物制药股份有限公司 2025 年第一次临时股东大会的 法律意见书 二〇二五年八月 北京市东城区东直门南大街 1 号来福士中心办公楼 12 层 邮编：100007 12th Floor, Raffles City Beijing Office Tower, No.1 Dongzhimen South Street, Dongcheng District, Beijing 100007 P.R.C 电话(Tel)：010-56500900 传真(Fax)：010-56500999 www.meritsandtree.com 北京植德律师事务所 关于成都苑东生物制药股份有限公司 2025 年第一次临时股东大会的 法律意见书 植德京(会)字[2025]0104 号 致：成都苑东生物制药股份有限公司（贵公司） 北京植德律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出 席并见证贵公司 2025 年第一次临时股东大会（以下简称"本次会议"）。 本所律师参加本次会议进行见证，并根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人 ...

Core Viewpoint - The article highlights the strong performance of brokerage "gold stocks" in July, with all 30 brokerage gold stock combinations showing positive returns, indicating a robust recovery in the A-share market [2][9]. Brokerage Performance - Ping An Securities' gold stock combination achieved the highest return of 16.57% in July, followed by Kaiyuan Securities at 13.57% and Caitong Securities at 12.93% [3][9][10]. - Notably, all brokerage gold stock combinations recorded positive returns, with several brokerages, including China Merchants Securities and Galaxy Securities, also exceeding 10% returns [9][10]. Top Performing Stocks - The best-performing stock was Kangchen Pharmaceutical, recommended by Ping An Securities, which surged by 106.74% in July [4][6]. - Other notable stocks included Borui Pharmaceutical (82.05%), Kangfang Biotech (68.13%), and Yuandong Biotech (56.60%), all showing significant monthly gains [6][7]. August Strategy - Brokerages are adopting an aggressive strategy for August, focusing on technology growth stocks and cyclical stocks benefiting from mid-year performance reports [12][15]. - The market outlook is optimistic, driven by expectations of recovering corporate ROE and a favorable policy environment, suggesting a continued upward trend in A-shares [15]. Common Recommendations - Several stocks received multiple recommendations from brokerages for August, including Dongfang Caifu, Muyuan Foods, and Wanhua Chemical, each recommended by four different brokerages [16][19]. - The rationale for recommending Dongfang Caifu includes the potential for the securities sector to enter a main upward trend, while Muyuan Foods is recognized for its leading position in the pig farming industry [16][19].

Group 1 - The core viewpoint highlights the active trading and significant growth of the Science and Technology Innovation (Sci-Tech) Pharmaceutical ETF managed by Harvest, with a turnover rate of 21.72% and a transaction volume of 47.63 million yuan on July 31 [2] - Over the past week, the Sci-Tech Pharmaceutical ETF has seen an average daily transaction volume of 53.21 million yuan, ranking first among comparable funds [2] - The fund's scale increased by 16.78 million yuan in the past week, also leading among comparable funds, with a share increase of 12.50 million shares [2] Group 2 - The fund has attracted a total of 14.72 million yuan in inflows over the last five trading days [2] - As of July 31, the net value of the Sci-Tech Pharmaceutical ETF has risen by 48.77% over the past year, ranking 350 out of 2943 in the index stock fund category, placing it in the top 11.89% [2] - The fund's highest monthly return since inception was 23.29%, with the longest consecutive monthly gain being six months and a maximum increase of 41.76% [2] Group 3 - The top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index account for 49.14% of the index, with leading companies including United Imaging Healthcare and BeiGene [2] - The stock performance of the top ten companies shows mixed results, with some stocks experiencing slight declines while others have positive growth [4] Group 4 - The National Healthcare Security Administration has established a "new drug first launch price mechanism" to encourage drug research and innovation, marking a significant policy development [4] - The pharmaceutical and biotech sectors are expected to benefit from a high level of innovation and a potential revaluation of value stocks, with recommendations for companies in the Pharma and Biopharma/Biotech sectors [5] - The medical device industry is also anticipated to benefit from policy optimizations, with recent statements from relevant authorities supporting innovation and addressing issues of internal competition [5]